N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence.
Loading...
Date
2016-04
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
As millions of surgical procedures are performed worldwide on an aging population with multiple comorbidities,
accurate and simple perioperative risk stratification is critical. The cardiac biomarker, brain natriuretic
peptide (BNP), has generated considerable interest as it is easy to obtain and appears to have powerful
predictive and prognostic capabilities. BNP is currently being used to guide medical therapy for heart failure
and has been added to several algorithms for perioperative risk stratification. This review examines the current
evidence for the use of BNP in the perioperative period in patients who are at high‑cardiovascular risk for
noncardiac surgery. In addition, we examined the use of BNP in patients with pulmonary embolism and left
ventricular assist devices. The available data strongly suggest that the addition of BNP to perioperative risk
calculators is beneficial; however, whether this determination of risk will impact outcomes, remains to be seen.
Description
Keywords
Brain natriuretic peptide, Noncardiac surgery, Perioperative risk
Citation
Malhotra Anita K, Ramakrishna Harish. N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence. Annals of Cardiac Anaesthesia. 2016 Apr; 19(2): 314-320.